Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Her2climb 05.
Addition of Tucatinib to HP maintenance leads to absolute benefit of 8.6 months In median PFS.
Os immature.
Benefit to both Hr positive and negative pts.
Patina vs DB09 vs Her2climb or mixed? Exciting times ahead.
Congratulations Erika Hamilton.”
More posts featuring Erika Hamilton on OncoDaily.
